About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
October 2019
Successful Treatment of a Patient with Retroperitoneal Abscess caused by
Candida krusei
with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study
George R. Thompson III, David Angulo
TIMM 2019
October 2019
Candida auris
is Highly
In Vitro
Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing
Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019
Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against
Candida auris: In Vitro, In Vivo
and Clinical Case Studies of Candidemia
S. Barat, D. Angulo
TIMM 2019
October 2019
Successful Treatment of a Patient with Retroperitoneal Abscess caused by
Candida krusei
with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study
GR Thompson, David Angulo
TIMM 2019
June 2019
Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of
Candida auris
Cutaneous Infection in a Guinea Pig Model
M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019
Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderua, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ASM Microbe 2019
April 2019
Successful Treatment of Two Patients with
Candida auris
Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study
D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019
Favourable Clinical Outcome of Two Patients with
Candida
spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study
Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
April 2019
Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study
J Vazquez, Aprile Osborn, D Angulo
ECCMID 2019
April 2019
Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderu, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ECCMID 2019
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility